tirzepatide cv outcomes trial Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist for type 2 diabetes: A systematic review and meta-analysis Original Article: Cardiovascular Outcomes with

But after month 5, the tirzepatide patients begin to pull away from the semaglutide patients

Mechanistic sub-study embedded in an efficacy trial + Incorporate GSM/dryness endpoints (validated questionnaires, clinician assessment, pH) into semaglutide RCTs or pragmatic trials, with pre-specified subgroup analyses by menopausal status and HRT use

Niacinamide formulations offer their own potential benefits

The primary symptom is fatigue, often accompanied by pale skin, cold hands and feet, and breathlessness during mild exertion

We encourage clients to schedule a consultation to discuss their options, including insurance coverage and pricing for approved medications